Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin
Michiko Yamamoto, Akira Takakura, Noriyuki MasudaDepartment of Respiratory Medicine, Kitasato University School of Medicine, Kitasato, JapanAbstract: Amrubicin is a totally synthetic anthracycline anticancer agent that acts as a potent topoisomerase II inhibitor. Amrubicin has been approved in Japan...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-09-01
|
| Series: | Drug Design, Development and Therapy |
| Online Access: | http://www.dovepress.com/next-generation-anthracycline-for-the-management-of-small-cell-lung-ca-a2275 |